Form 4: Surrozen Executive Yang Li Acquires 20,000 Stock Options

Executive Vice President of Research at Surrozen, Inc., Yang Li, reports the acquisition of 20,000 stock options.

Summary

• On May 1, 2024, Yang Li, the Executive Vice President of Research at Surrozen, Inc., acquired 20,000 stock options.
• The exercise price of these options is $9.89.
• The options vest in 48 equal monthly installments starting June 1, 2024, contingent upon continuous service.
• The expiration date for these options is May 1, 2034.
• Following the transaction, Yang Li directly owns 20,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is neither particularly positive nor negative on its own. The grant could be seen as a positive sign of incentivizing management, but it's also a cost to the company.

Positives

• The acquisition of stock options by a key executive could signal confidence in the company's future prospects.

Industry Context

This is a standard Form 4 filing, reflecting a common practice of granting stock options to executives as part of their compensation package. It's typical for biotech companies like Surrozen to use stock options to incentivize key personnel.

Comparison to Industry Standards

• Stock option grants are a common component of executive compensation packages in the biotechnology industry.
• Companies like Amgen, Gilead, and Regeneron also utilize stock options to align executive interests with shareholder value.
• The vesting schedule of 48 months is fairly standard within the industry.

Stakeholder Impact

• Shareholders may view the stock option grant as a way to align management's interests with the company's long-term success.
• Employees may see this as a positive sign of investment in the company's leadership.

Key Dates